Confronto

Ganirelix vs. Icatibant

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

123246-29-7

138614-30-9

Peso molecolare

1570.3 g/mol

1304.52 g/mol

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Ganirelix

Ganirelix competitively and reversibly binds the pituitary GnRH receptor, rapidly suppressing LH (and, less so, FSH) release — without the initial hormone 'flare' of GnRH agonists.

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Ganirelix	Icatibant
Germania	Su prescrizione	Su prescrizione
Stati Uniti	Su prescrizione	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Ganirelix and Icatibant?: Ganirelix is classified as "Ricerca (altro)", while Icatibant is classified as "Ricerca (altro)". Ganirelix: Ganirelix is a synthetic decapeptide and GnRH antagonist. In assisted reproduction (IVF) it prevents the premature LH surge during controlled ovarian stimulation. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Ganirelix or Icatibant?: The highest available evidence level is "RCT sull'uomo" for Ganirelix and "RCT sull'uomo" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Ganirelix and Icatibant in Germany and the United States?: Germania: Ganirelix — Su prescrizione, Icatibant — Su prescrizione. Stati Uniti: Ganirelix — Su prescrizione, Icatibant — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Ganirelix

Icatibant

Germania

Su prescrizione

Stati Uniti

Su prescrizione

Frequently asked questions

What is the difference between Ganirelix and Icatibant?

Ganirelix is classified as "Ricerca (altro)", while Icatibant is classified as "Ricerca (altro)". Ganirelix: Ganirelix is a synthetic decapeptide and GnRH antagonist. In assisted reproduction (IVF) it prevents the premature LH surge during controlled ovarian stimulation. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Ganirelix or Icatibant?

The highest available evidence level is "RCT sull'uomo" for Ganirelix and "RCT sull'uomo" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Ganirelix and Icatibant in Germany and the United States?

Germania: Ganirelix — Su prescrizione, Icatibant — Su prescrizione. Stati Uniti: Ganirelix — Su prescrizione, Icatibant — Su prescrizione. These are factual summaries with source and review date on the individual pages.